$SYRE insider trading
Over the last 12 months, Spyre Therapeutics insiders reported no purchases and 33 sales totaling $436.7M across SEC Form 4 filings. 94% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $436.7M 33 events
- Events · 12m
- 33 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 94% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | King-Jones HeidySee Remarks · O | ▼ Sale | 28,399 | $87.35 | $2.5M | -90.9% | plan · 5 tranches |
| Sep 2, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 25,732 | $88.75 | $2.3M | -24.4% | plan · 5 tranches |
| Sep 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $87.29 | $1.3M | -2.6% | plan · 4 tranches |
| Aug 7, 2026 | Albers Jeffrey W.D | ▼ Sale | 18,000 | $104.55 | $1.9M | -65.8% | plan · 2 tranches · indirect |
| Aug 7, 2026 | Albers Jeffrey W.D | ▼ Sale | 5,000 | $104.47 | $522K | -100% | plan |
| Aug 3, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 7,500 | $95.57 | $717K | -7.1% | plan · 3 tranches |
| Aug 3, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $95.51 | $1.4M | -2.6% | plan · 5 tranches |
| Jul 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 7,500 | $87.74 | $658K | -7.1% | plan · 2 tranches |
| Jul 1, 2026 | Sloan SheldonChief Medical Officer · O | ▼ Sale | 8,334 | $87.7 | $731K | -100% | plan · 2 tranches |
| Jul 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $87.69 | $1.3M | -2.5% | plan · 3 tranches |
| Jun 25, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 15,000 | $87.13 | $1.3M | -13.3% | 2 tranches |
| Jun 23, 2026 | Fairmount Funds Management LLCD | ▼ Sale | 4,684,781 | $85.31 | $399.7M | -100% | indirect |
| Jun 22, 2026 | HENDERSON MICHAEL THOMASD | ▼ Sale | 20,000 | $100 | $2.0M | -22.6% | plan |
| Jun 3, 2026 | Sloan SheldonChief Medical Officer · O | ▼ Sale | 8,333 | $75 | $625K | -100% | plan |
| Jun 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 3,294 | $71.38 | $235K | -0.5% | plan |
| Jun 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 8,149 | $70.5 | $575K | -1.3% | plan |
| Jun 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 3,557 | $69.4 | $247K | -0.6% | plan |
| Jun 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 3,100 | $72.06 | $223K | -3.1% | plan |
| Jun 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 2,599 | $70.77 | $184K | -2.5% | plan |
| Jun 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 1,801 | $69.75 | $126K | -1.7% | plan |
| May 8, 2026 | HENDERSON MICHAEL THOMASD | ▼ Sale | 80,000 | $74.4 | $6.0M | -47.4% | plan · 4 tranches |
| May 1, 2026 | Sloan SheldonChief Medical Officer · O | ▼ Sale | 78,333 | $71.5 | $5.6M | -100% | plan · 7 tranches |
| May 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 12,500 | $71.37 | $892K | -11.3% | plan |
| May 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $71.37 | $1.1M | -2.4% | plan · 6 tranches |
| Apr 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 7,500 | $49.34 | $370K | -7.1% | plan · 2 tranches |
| Apr 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $49.33 | $740K | -2.3% | plan · 2 tranches |
| Apr 1, 2026 | Sloan SheldonChief Medical Officer · O | ▼ Sale | 7,958 | $50 | $398K | -100% | plan |
| Mar 3, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 2,500 | $40.65 | $102K | -2.5% | plan · 2 tranches |
| Mar 2, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $42.19 | $633K | -2.3% | plan · 2 tranches |
| Feb 2, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $32.8 | $492K | -2.2% | plan · 2 tranches |
| Jan 2, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $30.68 | $460K | -2.2% | plan · 3 tranches |
| Dec 1, 2025 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $29.02 | $435K | -2.1% | plan · 2 tranches |
| Nov 3, 2025 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 45,000 | $23.33 | $1.0M | -6% | plan · 2 tranches |
| Sep 2, 2025 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 18,428 | $16.26 | $300K | -15.8% | — |
Every $SYRE filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Spyre Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $SYRE feed.